Join to access to all OVN content. Join for Free
Trust, Transparency & Timelines: Advancing Cancer Care
Kirk Shepard Rebecca Goldstein

Trust, Transparency & Timelines: Advancing Cancer Care


Share This Article


Summary

In episode 2 of the Oncology Voice Network Podcast, Rebecca Goldstein joins Dr. Kirk Shepard to share her vision for the OVN community: a space where real collaboration happens between manufacturers and innovation partners, and both sides learn how to optimize this critical relationship. This is about every expert contributing freely so we can learn from one another and propel oncology forward faster.

What happens when true experts break down walls to speed up cancer cures?

In this episode of the Oncology Voice Network Podcast, host Dr. Kirk Shepard welcomes Rebecca Goldstein, VP of Strategy and Communications at OVN and a self-described “oncology lifer.” Dive into a raw, real-world conversation about the often-overlooked role of innovation partners in pushing oncology drug development forward.

Rebecca shares her journey from the lab bench to shaping cross-sector collaboration, revealing what sets innovation partners apart from traditional service providers. She and Dr. Shepard explore why transparent and timely communication isn’t just nice-to-have—it’s essential for real progress. They break down the high cost of information silos, why trust is a two-way street, and how the OVN community is opening new doors for experts, manufacturers, and innovators to learn from each other.

You’ll gain practical takeaways on building powerful, trust-based relationships that break through bureaucracy and accelerate patient impact, plus a behind-the-scenes look at the making of Voices of Oncology and how competition gave way to collaboration.

Ready to see how a new culture of partnership can transform cancer drug development? Tune in and join the conversation.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology
OVN Avatar Joe Pardavila sits down with Dr. Ramin Farhood and Dr. Kirk Shepard

Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology

Podcast
How to Accelerate Cancer Cures Through Collaboration with Kirk V. Shepard, MD
Partner Avatar Michael Pietrack

How to Accelerate Cancer Cures Through Collaboration with Kirk V. Shepard, MD

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN